MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

Licensed in from Ablynx in 2013 five years before a merger with Sanofi, German Merck recognised its potential. "There’s also a 'mystery CEO' that MoonLake has yet to unveil, who had the clout to ...

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA.

Merck (MRK) has reportedly been in talks to acquire Swiss biotech company MoonLake Immunotherapeutics (MLTX) for over $3 billion, according to the Financial Times. Snowflake (SNOW) will buy ...

Merck (MRK) has reportedly been in talks to acquire Swiss biotech company MoonLake Immunotherapeutics (MLTX) for over $3 billion, according to the Financial Times. Snowflake (SNOW) will buy startup ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...